Study guide
11.2 High-Risk Drug Classes & Prescribing Safety
MRCPI in General Medicine Part I Written
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Strategy & Foundation
1.1 MRCPI Part I Format, Scoring & Standard-Setting 1.2 RCPI BST Curriculum & Single-Best-Answer Exam Strategy
2 Chapter 2: Cardiology & Vascular Medicine
2.1 Acute Coronary Syndromes & Stable Angina 2.2 Tachyarrhythmias, Bradyarrhythmias & Channelopathies 2.3 Heart Failure & Valvular Heart Disease 2.4 Hypertension, Vascular & Pericardial Diseases
3 Chapter 3: Respiratory Medicine
3.1 Asthma, COPD & Airway Diseases 3.2 Pneumonia, Tuberculosis & Respiratory Infections 3.3 Interstitial Lung Disease & Pleural Disorders 3.4 Pulmonary Embolism, Pulmonary Hypertension & Sleep Apnoea
4 Chapter 4: Gastroenterology & Hepatology
4.1 Upper & Lower GI Disorders & Inflammatory Bowel Disease 4.2 Acute & Chronic Liver Disease 4.3 Pancreatitis, Biliary Tract & GI Bleeding 4.4 Malabsorption, GI Motility & Clinical Nutrition
5 Chapter 5: Nephrology & Acid-Base Disorders
5.1 Acute Kidney Injury & Glomerular Diseases 5.2 Chronic Kidney Disease & Renal Replacement Therapy 5.3 Electrolyte Imbalances & Acid-Base Disorders
6 Chapter 6: Endocrinology & Diabetes
6.1 Diabetes Mellitus & Metabolic Complications 6.2 Thyroid & Calcium Disorders 6.3 Adrenal, Pituitary & Endocrine Syndromes
7 Chapter 7: Rheumatology & Clinical Immunology
7.1 Inflammatory Arthritides 7.2 Systemic Autoimmune & Vasculitic Diseases 7.3 Metabolic Bone Disease & Clinical Immunology
8 Chapter 8: Haematology & Medical Oncology
8.1 Anaemias, Haemostasis & Thrombosis 8.2 Leukaemias, Lymphomas & Plasma Cell Disorders 8.3 Medical Oncology & Oncological Emergencies
9 Chapter 9: Neurology & Dermatology
9.1 Stroke & Cerebrovascular Diseases 9.2 Epilepsy, Headache & Movement Disorders 9.3 Neuromuscular & Peripheral Nerve Disorders 9.4 Cutaneous Manifestations of Systemic Disease
10 Chapter 10: Acute Medicine, Critical Care & Geriatrics
10.1 Acute Poisoning & Toxidromes 10.2 Sepsis, Shock & Resuscitation 10.3 Geriatric Syndromes, Frailty & Comprehensive Care
11 Chapter 11: Clinical Pharmacology & Therapeutics
11.1 Pharmacokinetics & Pharmacodynamics 11.2 High-Risk Drug Classes & Prescribing Safety 11.3 Adverse Drug Reactions & Drug Safety
12 Chapter 12: Basic Sciences, Biostatistics & Clinical Ethics
12.1 Applied Cardiovascular & Respiratory Physiology 12.2 Clinical Biochemistry, Molecular Genetics & Microbiology 12.3 Biostatistics, Evidence-Based Medicine & Ethics
11.2 High-Risk Drug Classes & Prescribing Safety
Key Takeaways Explain This Topic AI
Direct Oral Anticoagulants (DOACs) require strict renal dose adjustments; specific reversing agents are idarucizumab for dabigatran and andexanet alfa for factor Xa inhibitors (apixaban, rivaroxaban, edoxaban).
Insulin is a high-alert medication responsible for ~15% of inpatient medication errors; orders must specify brand name, formulation, and exact numeric units (never abbreviating 'U' or 'IU').
Once-daily aminoglycoside dosing (5–7 mg/kg gentamicin based on ideal body weight) optimizes peak-to-MIC bactericidal efficacy while minimizing renal cortical accumulation and nephrotoxicity.
Methotrexate for autoimmune inflammatory disease MUST be prescribed ONCE WEEKLY on a designated day, with folic acid 5 mg prescribed on a separate day to avoid fatal pancytopenia.
Opioid conversion requires a 30–50% dose reduction for incomplete cross-tolerance; in renal failure (eGFR <30 mL/min), morphine and codeine accumulate neurotoxic metabolites and must be substituted with fentanyl or alfentanil.
Last updated: July 2026
High-Risk Drug Classes & Prescribing Safety
Prescribing safety relies on identifying high-risk medication categories—frequently designated by the acronym APINCH (Anticoagulants, Potassium/Insulin, Narcotics/Opioids, Chemotherapeutic/Immunosuppressive agents, and High-concentration sedatives). Errors involving these classes account for over 50 % 50\% 50% of preventable drug-related deaths in hospitalized patients.
Anticoagulation Prescribing & Reversal Protocols
Anticoagulants are vital for stroke prevention in atrial fibrillation and treatment of venous thromboembolism (VTE), but carry high risks of life-threatening hemorrhage.
Warfarin Management
Mechanism : Inhibits Vitamin K Epoxide Reductase Complex 1 (VKORC1), blocking γ \gamma γ -carboxylation of Factors II, VII, IX, X, and proteins C/S.
Monitoring : International Normalized Ratio (INR). Target INR is 2.0 − 3.0 2.0-3.0 2.0 − 3.0 for AF, DVT, and PE, or 2.5 − 3.5 2.5-3.5 2.5 − 3.5 for mechanical mitral heart valves.
Direct Oral Anticoagulants (DOACs)
Direct Thrombin Inhibitor : Dabigatran etexilate (150 mg BD).
Direct Factor Xa Inhibitors : Apixaban (5 mg BD), Rivaroxaban (20 mg OD with food), Edoxaban (60 mg OD).
Renal Cut-offs :
Dabigatran : Contraindicated if eGFR < 30 mL/min \text{eGFR} < 30 \text{ mL/min} eGFR < 30 mL/min .
Apixaban : Standard dose 5 mg BD. Reduce to 2.5 mg BD if patient meets ≥ 2 \ge 2 ≥ 2 of: Age ≥ 80 \ge 80 ≥ 80 years, Body weight ≤ 60 kg \le 60 \text{ kg} ≤ 60 kg , Serum creatinine ≥ 133 μ mol/L \ge 133 \ \mu\text{mol/L} ≥ 133 μ mol/L . Contraindicated if eGFR < 15 mL/min \text{eGFR} < 15 \text{ mL/min} eGFR < 15 mL/min .
Rivaroxaban/Edoxaban : Dose reduction required if eGFR 15 − 49 mL/min \text{eGFR } 15-49 \text{ mL/min} eGFR 15 − 49 mL/min ; avoid if eGFR < 15 mL/min \text{eGFR} < 15 \text{ mL/min} eGFR < 15 mL/min .
Clinical Table: Emergency Anticoagulation Reversal Protocols
Anticoagulant Clinical Indication for Reversal First-Line Emergency Reversing Agent Alternative / Adjunctive Measures
Warfarin Major / Life-threatening bleeding (e.g., ICH) 4-Factor Prothrombin Complex Concentrate (PCC) ( 25 – 50 units/kg 25–50 \text{ units/kg} 25–50 units/kg IV) + IV Phytomenadione (Vitamin K1) 5 – 10 mg 5–10 \text{ mg} 5–10 mg Fresh Frozen Plasma (FFP 15 mL/kg 15 \text{ mL/kg} 15 mL/kg ) only if PCC unavailable.
Warfarin Non-major bleeding, INR > 8.0 > 8.0 > 8.0 Stop warfarin; give Oral Vitamin K1 1 – 5 mg 1–5 \text{ mg} 1–5 mg Recheck INR in 24 hours.
Dabigatran Life-threatening bleeding or emergency surgery Idarucizumab (Praxbind) 5 g 5 \text{ g} 5 g IV (given as two 2.5 g 2.5 \text{ g} 2.5 g boluses) Tranexamic acid ( 1 g 1 \text{ g} 1 g IV); Hemodialysis removes ≈ 60 % \approx 60\% ≈ 60% of dabigatran.
Rivaroxaban / Apixaban Life-threatening bleeding Andexanet alfa (Anindexa) recombinant inactive Factor Xa decoy 4-Factor PCC ( 50 units/kg 50 \text{ units/kg} 50 units/kg IV) if Andexanet unavailable.
Unfractionated Heparin (UFH) Severe bleeding or protamine neutralization post-CPB Protamine Sulfate ( 1 mg 1 \text{ mg} 1 mg per 100 units UFH given in past 2 − 4 hours 2-4 \text{ hours} 2 − 4 hours , max 50 mg 50 \text{ mg} 50 mg ) Rapid reversal within minutes.
LMWH (Enoxaparin) Major bleeding within 8 hours of dose Protamine Sulfate ( 1 mg 1 \text{ mg} 1 mg per 1 mg 1 \text{ mg} 1 mg enoxaparin) Achieves only partial reversal ( ≈ 60 − 75 % \approx 60-75\% ≈ 60 − 75% anti-Xa activity).
Insulins and Inpatient Glycemic Safety
Insulin errors represent 15 % 15\% 15% of high-alert hospital medication safety incidents, caused primarily by confusion between generic names, incorrect concentrations, or illegible dosage abbreviations.
Prescribing Mandates :
Always prescribe insulin by brand name (e.g., Lantus , Toujeo , Abasaglar , Novorapid , Humalog , Actrapid ). Different formulations of insulin glargine (e.g., Lantus 100 units/mL vs Toujeo 300 units/mL) are non-interchangeable on a unit-for-unit basis.
Write "units" in full. Never use "U" or "IU", which are easily misread as a zero (0) or number four (4), resulting in tenfold overdose (e.g., 10 U read as 100 units).
Inpatient Hypoglycemia Protocol ( Blood Glucose < 4.0 mmol/L \text{Blood Glucose} < 4.0 \text{ mmol/L} Blood Glucose < 4.0 mmol/L ) :
Conscious patient : 15 − 20 g 15-20 \text{ g} 15 − 20 g fast-acting carbohydrate (e.g., 200 mL 200 \text{ mL} 200 mL orange juice or 4-5 glucotabs), followed by complex carbohydrate.
Unconscious / NPO / Severe : IV access present → 75 − 100 mL \rightarrow 75-100 \text{ mL} → 75 − 100 mL of 20% Glucose IV over 15 minutes (or 150 − 200 mL 150-200 \text{ mL} 150 − 200 mL 10% Glucose). If no IV access → \rightarrow → IM Glucagon 1 mg .
Oral Antidiabetic Safety :
Metformin : Hold prior to iodinated contrast media if eGFR < 45 mL/min \text{eGFR} < 45 \text{ mL/min} eGFR < 45 mL/min . Discontinue permanently if eGFR < 30 mL/min \text{eGFR} < 30 \text{ mL/min} eGFR < 30 mL/min due to risk of metformin-associated lactic acidosis (MALA).
Sulfonylureas (Gliclazide) : Accumulate in renal impairment, causing severe, prolonged hypoglycemia requiring extended observation ( > 24 hours >24 \text{ hours} > 24 hours ) and IV glucose infusions.
Aminoglycoside Prescribing: Extended-Interval (Once-Daily) Dosing
Once-daily gentamicin ( 5 − 7 mg/kg 5-7 \text{ mg/kg} 5 − 7 mg/kg ) utilizes concentration-dependent bactericidal killing ( Peak / MIC ≥ 8 − 10 \text{Peak}/\text{MIC} \ge 8-10 Peak / MIC ≥ 8 − 10 ) and the post-antibiotic effect (PAE) , while protecting the renal cortex and inner ear through an extended low-trough washout period.
Dosing Weight : Calculate dosage using Ideal Body Weight (IBW) . In obese patients ( BMI ≥ 30 kg/m 2 \text{BMI} \ge 30 \text{ kg/m}^2 BMI ≥ 30 kg/m 2 ), use Adjusted Body Weight: Adjusted Weight = IBW + 0.4 × ( Actual Weight − IBW ) \text{Adjusted Weight} = \text{IBW} + 0.4 \times (\text{Actual Weight} - \text{IBW}) Adjusted Weight = IBW + 0.4 × ( Actual Weight − IBW )
Monitoring : Measure serum concentration 18–24 hours after the first dose. Plot on Hartford nomogram or ensure trough level is < 1.0 mg/L < 1.0 \text{ mg/L} < 1.0 mg/L prior to the second dose.
Exclusions from Once-Daily Dosing : Infective endocarditis (requires synergistic low-dose gentamicin 1 mg/kg 1 \text{ mg/kg} 1 mg/kg BD/TID), severe burns, ascites, pregnancy, or eGFR < 20 mL/min \text{eGFR} < 20 \text{ mL/min} eGFR < 20 mL/min . Use conventional multiple-daily dosing in these settings.
- Immunosuppressant Safety: Methotrexate and Azathioprine
- Methotrexate Prescribing Standards
Frequency : Prescribed ONCE WEEKLY on a designated day of the week (e.g., every Monday) for rheumatoid arthritis, psoriasis, or inflammatory bowel disease. Daily dosing leads to fatal bone marrow suppression and gastrointestinal mucositis.
Folic Acid Supplementation : Prescribe Folic Acid 5 mg 5 \text{ mg} 5 mg once weekly on a different day (e.g., Friday) to minimize mucosal and hematological toxicity without attenuating therapeutic efficacy.
Pre-treatment Screening : Baseline FBC, LFTs, Renal function, and Chest X-ray (to exclude baseline pulmonary fibrosis).
Drug Interactions : NSAIDs, co-trimoxazole, and penicillins reduce renal tubular excretion of methotrexate, precipitating acute toxicity.
Toxicity Rescue : Calcium folinate (leucovorin) is the specific rescue agent for methotrexate toxicity.
Azathioprine & Allopurinol Interaction
TPMT Screening : Test thiopurine S-methyltransferase (TPMT) activity before initiating azathioprine or 6-mercaptopurine. Homozygous TPMT deficiency ( 0.3 % 0.3\% 0.3% of population) causes profound aplastic anemia.
Major Allopurinol Interaction : Allopurinol and febuxostat inhibit xanthine oxidase , the enzyme responsible for inactivating 6-mercaptopurine. Co-administration increases active 6-thioguanine nucleotides by 4-fold to 5-fold. If co-administration is unavoidable, the azathioprine dose MUST be reduced by 75% ( 1 / 4 1/4 1/4 of original dose) with weekly FBC monitoring.
Opioid Equianalgesic Dosing & Safety
Opioid prescribing requires strict calculation of equianalgesic ratios to prevent accidental fatal hypoventilation.
Breakthrough Pain Calculation
The breakthrough dose of immediate-release opioid equals 1 / 10 th 1/10\text{th} 1/10 th to 1 / 6 th 1/6\text{th} 1/6 th of the total 24-hour baseline oral morphine equivalent dose, administered every 2 to 4 hours as needed.
Opioid Rotation Ratios & Cross-Tolerance
When switching between opioids, calculate the total daily oral morphine equivalent, apply the conversion factor, and then reduce the calculated dose by 30% to 50% to account for incomplete cross-tolerance.
Transdermal Fentanyl Patch : Oral morphine 60 − 100 mg/24h ≈ Fentanyl patch 25 μ g/h 60-100 \text{ mg/24h} \approx \text{Fentanyl patch } 25 \ \mu\text{g/h} 60 − 100 mg/24h ≈ Fentanyl patch 25 μ g/h (changed every 72 hours). Patches are unsuitable for acute unstable pain due to slow onset ( 12 − 24 hours 12-24 \text{ hours} 12 − 24 hours to steady state).
Renal Impairment & Opioid Selection
Morphine & Codeine : Metabolized to morphine-3-glucuronide (M3G, neurotoxic causing myoclonus and hyperalgesia) and morphine-6-glucuronide (M6G, potent opioid agonist causing severe sedation and respiratory depression). Both accumulate rapidly when eGFR < 30 mL/min \text{eGFR} < 30 \text{ mL/min} eGFR < 30 mL/min .
Safe Opioids in CKD Stage 4-5 ( eGFR < 30 mL/min \text{eGFR} < 30 \text{ mL/min} eGFR < 30 mL/min ) : Fentanyl , Alfentanil , and Buprenorphine . These agents produce inactive metabolites and do not depend on renal excretion.
Exam Pearls
MRCPI Exam Pearl : Co-prescribing Allopurinol and Azathioprine without reducing the azathioprine dosage by 75 % 75\% 75% is a classic MRCPI safety scenario. Allopurinol blocks xanthine oxidase, leading to catastrophic bone marrow aplasia and life-threatening pancytopenia.
MRCPI Exam Pearl : In patients with severe renal impairment ( eGFR < 30 mL/min \text{eGFR} < 30 \text{ mL/min} eGFR < 30 mL/min ), morphine accumulation causes respiratory arrest due to M6G retention. The opioid of choice for severe pain in advanced CKD or dialysis is Fentanyl or Alfentanil.